Energy Balance, Polymorphisms in the mTOR Pathway, and Renal Cell Carcinoma Risk

Author： Shu Xiang   Lin Jie   Wood Christopher G.   Tannir Nizar M.   Wu Xifeng  

Publisher： Oxford University Press

ISSN： 1460-2105

Source： Journal of the National Cancer Institute, Vol.105, Iss.6, 2013-03, pp. : 424-432

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Efficacy of re-challenging metastatic renal cell carcinoma with mTOR inhibitors

By Roca Sophie   Quivy Amandine   Gross-Goupil Marine   Bernhard Jean-Christophe   De Clermont Henri   Ravaud Alain  

Acta Oncologica, Vol. 50, Iss. 7, 2011-10 ,pp. : 1135-1136

Informa Healthcare

Access to resources Recommend Favorite

Silibinin induces apoptosis through inhibition of the mTOR-GLI1-BCL2 pathway in renal cell carcinoma

By                          

Oncology Reports, Vol. 34, Iss. 5, 2015-01 ,pp. : 2461-2468

Spandidos Publications

Access to resources Recommend Favorite

Downregulation of cancer stem cell properties via mTOR signaling pathway inhibition by rapamycin in nasopharyngeal carcinoma

By                        

International Journal of Oncology, Vol. 47, Iss. 3, 2015-01 ,pp. : 909-917

Spandidos Publications

Access to resources Recommend Favorite

Interferonα enhances the susceptibility of renal cell carcinoma to rapamycin by suppressing mTOR activity

By          

Experimental and Therapeutic Medicine, Vol. 8, Iss. 1, 2014-01 ,pp. : 267-273

Spandidos Publications

Access to resources Recommend Favorite

Future directions of mammalian target of rapamycin (mTOR) inhibitor therapy in renal cell carcinoma

By Pal Sumanta  

Targeted Oncology, Vol. 6, Iss. 1, 2011-03 ,pp. : 5-16

Springer Publishing Company

Access to resources Recommend Favorite